BD announces major acquisitions to expand into new markets

On December 2, 2021, BD announced that it has acquired Venclose, a solution provider for the treatment of chronic venous insufficiency (CVI)-a disease caused by valve dysfunction that can lead to varicose veins
.
Radiofrequency ablation is the main treatment for CVI and is widely accepted by doctors
.
Compared with CVI's alternative laser treatment, radiofrequency ablation catheters can potentially reduce postoperative pain and bruising in patients
.
Venclose is a leader in the field of CVI treatment, and its innovative radio frequency (RF) ablation technology platform is designed to achieve versatility, efficiency and simplicity
.
Expansion of the venous ablation line CVI represents a significant and growing need for treatment within the healthcare system-affecting up to 40% of women and 17% of men in the United States
.
Venclose is a leader in the field of CVI treatment, and its innovative radio frequency (RF) ablation technology platform is designed to achieve versatility, efficiency and simplicity
.
Radiofrequency ablation is the main treatment for CVI and is widely accepted by doctors
.
Compared with CVI's alternative laser treatment, radiofrequency ablation catheters can potentially reduce postoperative pain and bruising in patients
.
"We are committed to setting a new standard of excellence for patients with venous diseases.
This requires first and foremost to provide doctors with innovative technologies," said Paddy OBrien, global president of BD Peripheral Intervention
.
"Our acquisition of Venclose will allow us to provide a more powerful portfolio of solutions for doctors who treat various venous diseases.
The
Venclose™ radiofrequency ablation system strategically complements our portfolio of leading venous disease technologies and remains in line with our focus Unanimous innovation provides transformative solutions to improve the treatment of chronic diseases and make it possible to transition to a new care environment
.
" The Venclose™ system is compact in design and provides two heating lengths (2.
5 Cm and 10 cm)
.
This kind of dynamic dual-heated length catheter provides doctors with multiple operating advantages
.
The heating length of the Venclose™ system is 30% longer than the longest leading competitive RF ablation catheter, allowing doctors to effectively ablate more veins in each heating cycle and help reduce the total number of ablations required for vein treatment
.
The dual heating length means that doctors can use the same catheter to ablate long and short venous segments-compared to catheters with shorter and/or static heating length dimensions, reducing the burden of inventory management
.
The system's technology is also designed to help provide patient-centered care
.
For example, its touch screen display provides real-time program data to help inform doctors of treatment decisions
.
The system also provides an audible tone for heat transfer—allowing doctors to focus more time and attention on the patient
.
Venclose was established in 2014 to enhance the treatment of CVI through radiofrequency ablation technology
.
The company has since been committed to providing technical advancement and procedural efficiency for doctors treating CVI, while also helping to improve patient satisfaction
.
The Venclose™ system is currently available in various healthcare organizations in the United States and Europe
.
The terms of the transaction were not disclosed
.
The transaction is expected to be irrelevant to BD's fiscal year 2022 financial results
.
Ten-billion-level market In 2020, the global peripheral vascular medical device market is expected to reach 8.
92 billion U.
S.
dollars (equivalent to RMB 56.
8 billion), and the United States is still the world's largest market
.
Intravenous intervention is a part of the peripheral intervention market, and the domestic intravenous intervention market is growing rapidly
.
In 2013, China's intravenous interventional device market scale was only 370 million yuan
.
In 2017, the venous interventional market has grown to 890 million yuan.
This rapid growth trend will rise rapidly with the growth of venous interventional surgery in clinical applications.
By 2022, the market size will reach 3.
10 billion yuan, a compound annual growth rate.
The rate will reach 28.
4%
.
According to statistics, 100,000 to 300,000 people die from venous thrombosis in the United States each year, and 500,000 people die from venous thrombosis each year in Europe
.
In 2019, the number of patients with varicose veins in China reached 390 million; there were 1.
5 million patients with deep vein thrombosis; the incidence of iliac vein compression was 700,000, and it is expected to reach 2 million by 2030
.
With the collection of coronary stents, the focus of vascular intervention has shifted from the coronary artery area to the neurovascular and peripheral blood vessels
.
Peripheral intervention is divided into peripheral arterial intervention and peripheral venous intervention
.
Intravenous intervention started late but developed rapidly
.
According to the calculation of Industrial Securities, the market value of China's venous interventional devices for the treatment of common venous diseases such as varicose veins, deep vein thrombosis and iliac vein compression syndrome is approximately 19.
46 billion
.
This tens of billions of peripherals involved in the competition for hegemony in the market attracted multinational giants such as BD, Medtronic, and Boston Scientific.
They entered the market early, with large-scale enterprises, and formed a rich product line
.
Local companies have also risen one after another.
Companies such as Lifetech and Guichuangtongqiao have reserved abundant R&D pipelines in the intravenous field
.
Domestic vein ablation pattern With the standardization of minimally invasive varicose veins, minimally invasive treatment will replace traditional surgery, and the amount of surgery will continue to grow rapidly
.
In minimally invasive therapies, radiofrequency ablation (RFA) and intracavitary laser ablation (EVLA) are two evidence-proven treatment methods for ablation therapies.
RFA accounted for more than 70% of the intracavitary thermal ablation operations in China in 2019
.
There are currently two types of radiofrequency ablation systems approved in China.
There are mainly three types of peripheral radiofrequency ablation catheters on sale in China, all manufactured by foreign companies, namely Medtronic’s Closure Fast and Closure RFS, and F Care Systems NV’s EVRF venous cavity Internal radio frequency closure system
.
The innovative direction of radiofrequency ablation products focuses on reducing complications
.
Complications of existing radiofrequency ablation products are mainly skin burns, vein splits, subcutaneous ecchymosis and swelling, and saphenous nerve damage
.
Controlling energy, subcutaneous injection of swelling fluid and continuous pressure therapy can effectively reduce complications
.
The thermal ablation technique requires the use of tumescent anesthesia before energy delivery, which may cause discomfort to the patient and may extend the operation time
.
For this reason, Medtronic focused on the normal temperature closure product VenaSeal.
The principle of the closure system is to inject adhesive into the vein through a catheter to achieve the effect of closing the vein
.
VenaSeal was approved by the FDA in 2015 and has become the main growth point of Medtronic's peripheral business in recent years.
The product has not yet been marketed in China
.
Domestic companies currently focus on the localization of radiofrequency ablation products for the ablation treatment of varicose veins, and reduce the complications of thermal ablation products; the adjustable, controllable and intelligent radiofrequency ablation system will greatly reduce the difficulty of the operation, which is important for product improvement.
Direction
.
Domestic R&D companies for radiofrequency ablation products include Xerida and Guichuangtongqiao
.
Unsatisfied market demand drives many companies to gather on this track, and competition in this field will become fierce in the future
.
From the perspective of domestic participants, the competitive landscape of the domestic intravenous interventional market has also initially emerged.
The main participants include multinational companies represented by Medtronic, Boston Scientific, and BD Medical; Leaders, as well as a group of emerging entrepreneurial companies
.